Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...
This next in a series of quick quizzes in dermatology asks -what’s the cause of this itchy, vesicular rash on the hands?
The FDA approved linerixibat (Lynavoy) as the first drug indicated for cholestatic pruritus stemming from primary biliary ...
The FDA has approved the first medication for cholestatic pruritus in adult patients with primary biliary cholangitis.The ...
The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.
Patients with primary biliary cholangitis (PBC) can use linerixibat to address cholestatic pruritus, which up to 89% of ...
Skin cancer is one of the most common types of cancer globally. Despite the remarkable advancements of deep learning methods in computer vision, automatic diagnosis of skin diseases still faces ...
The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS ...
Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the ...
Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results